We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hamburg: FDA Can Require Opioid Generics to Duplicate Brands’ Abuse-Deterrent Properties
Hamburg: FDA Can Require Opioid Generics to Duplicate Brands’ Abuse-Deterrent Properties
January 15, 2013
The FDA has the legal authority to require abuse-deterrent formulations of generic opioids if the generic’s branded counterpart is deemed to “significantly” deter abuse, Commissioner Margaret Hamburg told Congress.